Skip to content
DataLookout
Menu

NCT03709758

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 15 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 39 words
    • Study completion pushed from Sep 1, 2026 to Dec 1, 2026
    • Secondary endpoints: details revised at 3 of 4 entries
  2. Minor Study completion pushed from Jun 1, 2026 to Sep 1, 2026v14
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 64 to confirmed 50
    • Primary completion date changed from estimate of Dec 1, 2025 to Feb 23, 2025
    • Site details revised at 2 of 2 sites
    v13
  4. Notable Primary completion date: Dec 1, 2024 to Dec 1, 2025
    • Study completion date: Jun 1, 2025 to Jun 1, 2026
    v12
  5. Minor Primary completion date: Jul 1, 2024 to Dec 1, 2024v11
Show 9 earlier versionsHide 9 earlier versions
  1. Minor Study sites: 1 to 2v10
  2. Notable Primary completion date: Jan 1, 2024 to Jul 1, 2024v9
  3. Notable Trial status: Suspended to Recruiting
    • Primary completion date: Jun 1, 2023 to Jan 1, 2024
    • Site details revised
    v8
  4. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Accrual goal met, pending new cohort activation
    • Site details revised
    v7
  5. Minor Secondary endpoints: details revised at 1 of 4 entries
    • Site contact updated
    v6
  6. Minor Secondary endpoints: 3 to 4v5
  7. Minor Start date: Oct 15, 2018 to Oct 17, 2018v4
  8. Notable Eligibility criteria expanded, about 45 words
    • Enrollment target: 58 to 64
    v3
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 31, 2018 to Oct 15, 2018
    • Site details revised
    • Collaborators: 1 to 2
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum Tolerated Dose (Induction)
Timeframe: 2 years
Maximum Tolerated Dose (Consolidation)
Timeframe: 2 years

Secondary (4)

Complete Response Rate
Exploratory analysis concerning the impact of BH3 profiling on response when venetoclax is combined with standard induction and consolidation chemotherapy in AML.
Determine the pharmacodynamic effects of combo venetoclax with standard chemotherapy in AML on apoptosis and other intracellular events in AML blasts exposed in patients to a combination of venetoclax plus standard induction chemo.
Exploratory analysis concerning the impact of pre-therapy disease factors including mutational profile on outcome in AML patients who receive venetoclax in combination with standard chemotherapy.

Arms and interventions

Venetoclax+Daunorubicin+CytarabineExperimental

* Venetoclax administered orally on days 1 to 11 daily * Daunorubicin administered intravenously on days 2-4 * Cytarabine administered on days 2-8 by continuous IV infusion

Drugs: Venetoclax, Daunorubicin, Cytarabine

Sites

2 sites in 1 country